Last reviewed · How we verify
NCT03986437: MEDIRAD
A Prospective Study to Collect Images in Patients Treated With Iodine-131 as Part of a European Research Project in Radiation Protection.
trial in Differentiated Thyroid Cancer in 29 participants. Completed in 21 May 2021.
21 May 2021
Quick facts
| Lead sponsor | Institut Claudius Regaud |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 29 |
| Start date | 13 January 2020 |
| Primary completion | 21 May 2021 |
| Estimated completion | 21 May 2021 |
| Sites | 1 location across France |
Conditions studied
- Differentiated Thyroid Cancer — all drugs for Differentiated Thyroid Cancer →
Sponsor
Institut Claudius Regaud — full company profile →
Who can join
18 and older, any sex, with Differentiated Thyroid Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial is a prospective, non-interventional, monocentric study aiming to collect standard of care imaging of patients treated with Iodine-131 for the determination of dosimetric studies. Data from this study will be collected as part of an European research project called MEDIRAD. The overall objectives of this project are to enhance the scientific bases and clinical practice of radiation protection in the medical field, and more specifically to develop and implement the tools necessary to establish the range of absorbed doses delivered to healthy organs in patients undergoing thyroid ablation and the threshold absorbed dose required for thyroid ablation. This will enable patient specific treatment planning that will minimize risk to the patient while ensuring a successful outcome and will facilitate development of a large scale epidemiological study of the effect of low absorbed doses from irradiation of normal organs with internal sources of radionuclides. Patients will be followed as part of their standard of care. Imaging (SPECT/CT (Single Photon Emission Computed Tomography-Computerized Tomography) and Whole Body scintigraphy) performed at 48 hours post Iodine-131 treatment will be collected. Measures of external gamma radiation will also be collected in the European database.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03986437
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Differentiated Thyroid Cancer
Currently open trials in the same condition.
- NCT07436455 — F-18 Tetrafluoroborate PET/CT in Differentiated Thyroid Cancer · NA · recruiting
- NCT06458036 — Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE) · Phase 2 · recruiting
- NCT05783323 — Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer · Phase 2 · recruiting
- NCT05989425 — Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer · Phase 2 · recruiting
- NCT05599139 — Iodine Uptake After a Low Iodine Diet · NA · recruiting
Other Institut Claudius Regaud trials
Trials by the same sponsor.
- NCT07427186 — Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy of Immunotherapy in Patients With Early Stage · NA · not yet recruiting
- NCT07233928 — Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of Breast Canc · NA · recruiting
- NCT06967961 — Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers · NA · recruiting
- NCT06797037 — Proof of Concept to Assess the Feasibility of a Decentralised Pathway Coordinated by the Advanced Practice Nurse for Pat · NA · recruiting
- NCT06408038 — Are CK+/CD45+ Double-Positive Circulating Cells of Tumor-origin? Characterization in METAstatic Breast Cancer · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03986437 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institut Claudius Regaud
- Last refreshed: 27 May 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03986437.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing